A review published in The Annals of Pharmacotherapy looks at Yutrepia a dry powder form of inhaled treprostinil, and how it compares with the other inhaled treprostinil options for pulmonary arterial hypertension (PAH), in particular Tyvaso DPI. The authors searched the medical literature up to September 2026 and included twelve studies covering efficacy, safety, how the drug behaves in the body, switching between products, and how it is taken.
Key findings
No head-to-head trial has established superiority. Both dry powder formulations reduce nebulizer equipment burden, but current evidence does not establish greater efficacy, safety, adherence, or convenience for one dry powder product over the other.
Importantly, the authors stress that selection should be individualized, and inhaled therapy should not be considered equivalent to parenteral prostacyclin when parenteral treatment is clinically indicated.
Read more at this link on Sage Journals (only the abstract is open access)
Citation
Bui PT, Ramos E, Hammer J, Jarrard S, Nanda R. Treprostinil Inhalation Powder for Pulmonary Arterial Hypertension: Evidence and Clinical Positioning Among Inhaled Formulations. Ann Pharmacother. 2026 Oct 30:10600280261496878. doi: 10.1177/10600280261496878. Epub ahead of print. PMID: 42960619.
Summary by Suzanne Lea, volunteer for the Alliance for Pulmonary Hypertension